Stoke Therapeutics (STOK) News Today $8.45 -0.29 (-3.33%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan CapitalFebruary 21 at 2:55 AM | americanbankingnews.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday.February 20 at 8:05 AM | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) StockFebruary 20 at 2:39 AM | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Price Target Raised to $47.00HC Wainwright upped their price objective on Stoke Therapeutics from $35.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday.February 19 at 4:09 PM | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday.February 19 at 4:08 PM | marketbeat.comBiogen and Stoke Therapeutics to commercialise Dravet syndrome treatmentFebruary 19 at 8:32 AM | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 6.5% - Time to Sell?February 19 at 1:49 AM | marketbeat.comStoke Therapeutics price target raised to $47 from $35 at H.C. WainwrightFebruary 18 at 5:24 PM | markets.businessinsider.comBiogen continues dealmaking buzz with Stoke TherapeuticsFebruary 18 at 5:24 PM | bizjournals.comBiogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar DealFebruary 18 at 5:24 PM | finance.yahoo.comChardan Capital Sticks to Their Buy Rating for Stoke Therapeutics (STOK)February 18 at 5:24 PM | markets.businessinsider.comBiogen, Stoke Therapeutics Set Dravet Syndrome CollaborationFebruary 18 at 9:47 AM | marketwatch.comBiogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globallyFebruary 18 at 9:47 AM | msn.comBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsFebruary 18 at 8:00 AM | globenewswire.comStoke Therapeutics: A Pivotal Moment For This RNA PioneerFebruary 16, 2025 | seekingalpha.comStoke Therapeutics (NASDAQ:STOK) Trading Down 9.7% - Should You Sell?Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7% - What's Next?February 7, 2025 | marketbeat.comStoke City set to start consultation over club badgeFebruary 7, 2025 | msn.comStoke Therapeutics (NASDAQ:STOK) Shares Up 8.2% - What's Next?Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2% - Here's WhyFebruary 4, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for STOK FY2025 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($1.50) per share fJanuary 31, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have been given an average recommendation of "Buy" by the ten brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and oneJanuary 31, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading 6.9% Higher - What's Next?Stoke Therapeutics (NASDAQ:STOK) Trading 6.9% Higher - Time to Buy?January 29, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 5.6% - What's Next?Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 5.6% - Here's What HappenedJanuary 28, 2025 | marketbeat.comThe 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%January 27, 2025 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) Trading Up 6.3% - Here's What HappenedStoke Therapeutics (NASDAQ:STOK) Shares Up 6.3% - What's Next?January 23, 2025 | marketbeat.comBrokers Offer Predictions for STOK FY2025 EarningsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Stoke Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.40) per share for the year.January 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Raises Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Assenagon Asset Management S.A. grew its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,350,925 shares of the compJanuary 18, 2025 | marketbeat.comReusable rocket startup Stoke raised another massive round: $260MJanuary 16, 2025 | msn.comStoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7% - Time to Buy?Stoke Therapeutics (NASDAQ:STOK) Trading Up 9.7% - What's Next?January 15, 2025 | marketbeat.comWedbush Research Analysts Raise Earnings Estimates for STOKStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Wedbush lifted their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research note issued on Tuesday, January 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share ofJanuary 10, 2025 | marketbeat.comWhat is Wedbush's Forecast for STOK FY2029 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Wedbush issued their FY2029 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Wedbush analyst L. Chico forecasts that the company will post earnings oJanuary 9, 2025 | marketbeat.comPositive Outlook on Stoke Therapeutics: Strategic Alignment and Promising Data Reinforce Long-Term Growth PotentialJanuary 9, 2025 | markets.businessinsider.comThe Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 ExpertsJanuary 8, 2025 | benzinga.comStoke Therapeutics’ Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early ResultsJanuary 8, 2025 | markets.businessinsider.comStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | businesswire.comStoke Therapeutics (NASDAQ:STOK) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday.January 8, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Stoke Therapeutics (NASDAQ:STOK)Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday.January 8, 2025 | marketbeat.comStoke Therapeutics finalizes EMPEROR study program with regulatory agenciesJanuary 7, 2025 | markets.businessinsider.comStoke Therapeutics negative reaction after STK-001 update overdone, says ChardanJanuary 7, 2025 | msn.comBuy Rating on Stoke Therapeutics Driven by Promising Phase 3 Trial and Financial StabilityJanuary 7, 2025 | markets.businessinsider.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Time to Sell?Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's WhyJanuary 7, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by AnalystsShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and oneJanuary 6, 2025 | marketbeat.comFranklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)Franklin Resources Inc. lowered its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 98.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,314 shares of the company's stoJanuary 2, 2025 | marketbeat.comGeode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Geode Capital Management LLC increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 9.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 870,831 shares of the company's stock after purchasingJanuary 1, 2025 | marketbeat.comBarclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Barclays PLC increased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 145.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,740 shares of the company's stock after buying an addDecember 31, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 2.9% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Stock Price Down 2.9% - Here's WhyDecember 24, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street CorpState Street Corp raised its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 8.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,728,888 shares of the company's stock after acquiring an additional 137,1December 24, 2024 | marketbeat.comChardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy RecommendationDecember 20, 2024 | msn.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's What HappenedStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Time to Sell?December 20, 2024 | marketbeat.comChardan Capital Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK)Chardan Capital began coverage on shares of Stoke Therapeutics in a report on Friday. They set a "buy" rating and a $24.00 price objective for the company.December 20, 2024 | marketbeat.comJane Street Group LLC Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Jane Street Group LLC boosted its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 338.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,442 shares of the company's stock after buying an additionDecember 19, 2024 | marketbeat.com Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Media Mentions By Week STOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.270.60▲Average Medical News Sentiment STOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼206▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CNTA News BHC News HRMY News CGON News TARS News JANX News AGIO News NAMS News IDYA News SDGR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts